tailieunhanh - Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: Results from the ERIBEX retrospective, international, multicenter study

Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN